Vertex Pharmaceuticals Incorporated (VRTX) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
Recently, Zacks.com users have been paying close attention to Vertex (VRTX). This makes it worthwhile to examine what the stock has in store.
Vertex's new drugs are gaining momentum as Alyftrek tops $1 billion in sales and Journavx prescriptions accelerate.
Zacks.com users have recently been watching Vertex (VRTX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Vertex Pharmaceuticals Incorporated (VRTX) Q1 2026 Earnings Call Transcript
The headline numbers for Vertex (VRTX) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Vertex Pharmaceuticals (VRTX) came out with quarterly earnings of $4.47 per share, beating the Zacks Consensus Estimate of $4.23 per share. This compares to earnings of $4.06 per share a year ago.
Vertex (VRTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Vertex Pharmaceuticals (VRTX) reached $430.5 at the closing of the latest trading day, reflecting a -1.06% change compared to its last close.
These companies offer a clear path to sustained earnings growth.
The latest trading day saw Vertex Pharmaceuticals (VRTX) settling at $441.2, representing a +1.27% change from its previous close.
In the most recent trading session, Vertex Pharmaceuticals (VRTX) closed at $435.65, indicating a -1.37% shift from the previous trading day.